Japan’s medical device sector directly supports human health and life across diagnosis, treatment, monitoring and prevention. The domestic market has reached nearly USD 33 billion, while Kansai, particularly Kobe and Osaka, has developed into a major cluster of internationally active companies, including Sysmex, Nipro and Daiken Medical. Japan also has several hundred independent and semi-independent medical device distributors, specialist trading companies and regionally focused sales businesses, and M&A activity involving these companies has intensified in recent years.

This article examines Japan’s Medical Device Industry and M&A, outlines the structure of the market and recent transaction activity, and discusses the principal issues facing owners of mid-market and smaller companies considering succession and capital policy.

All USD figures in this article are approximate and converted at USD/JPY = 150 for reference.

Industry Structure: A USD 31.5 Billion Market, with Kansai as a Global Cluster for Diagnostics and Catheter-Related Businesses

According to the Ministry of Health, Labour and Welfare’s Annual Report on Statistics of Production by Pharmaceutical Industry for 2024, Japan’s medical device market recorded the following figures.

• Domestic production: USD 17.8 billion, down 0.4% year on year
• Imports: USD 24.0 billion, up 8.5% year on year
• Exports: USD 7.6 billion, up 1.7% year on year
• Domestic shipments: USD 31.5 billion, up 3.7% year on year

A notable feature of the market is that the value of imports exceeds domestic production. Advanced medical devices, particularly therapeutic devices, diagnostic imaging systems and robotic surgical equipment, continue to be dominated by US and European manufacturers. Japan remains one of the world’s largest medical device markets, but its structure continues to reflect a high degree of import dependence.

According to the Kansai Bureau of Economy, Trade and Industry’s data on the medical device and pharmaceutical sectors in Kansai, the region has developed into one of Japan’s principal medical and life-sciences clusters, centered on the Kobe Biomedical Innovation Cluster, Saito Life Science Park and Kansai Science City. Representative global companies in and around the region include the following.

• Sysmex Corporation (TSE Prime; headquartered in Chuo-ku, Kobe): Sysmex recorded revenue of USD 3.39 billion for the fiscal year ended March 2025 and holds a leading global position in hematology testing. Overseas revenue accounted for 86.7% of the total, and the company operates in more than 190 countries and regions, according to the Sysmex Report 2025.
• Nipro Corporation (TSE Prime; headquartered in Kita-ku, Osaka): A global manufacturer of dialysis, infusion and related medical equipment.
• Daiken Medical Co., Ltd. (TSE Prime; headquartered in Chuo-ku, Osaka): A specialist in anesthesia and postoperative pain-management equipment.
• Kawasumi Laboratories: A manufacturer associated with blood circuits, medical catheters and related products.

Kansai also has a large number of regionally focused medical device dealers and specialist trading companies. These businesses have become an important part of the current consolidation landscape.

Principal Drivers of Industry Consolidation

1. Rising costs of compliance with the Pharmaceuticals and Medical Devices Act and QMS requirements: Regulatory costs associated with manufacturing control and quality management weigh disproportionately on smaller businesses, increasing pressure for shared infrastructure and group integration.
2. Healthcare cost controls and pricing pressure: Revisions to medical reimbursement and the pricing system for specified reimbursable medical materials continue to compress margins, increasing the importance of scale.
3. Investment requirements for AI, robotic surgery and digital diagnostics: Research and development investment in new technologies is increasingly difficult for standalone smaller companies to fund.
4. Aging ownership: Many regional medical device distributors founded in the 1960s and 1970s are reaching a common generational transition point.
5. Roll-ups by global leaders: Companies such as Stryker, Medtronic, Johnson & Johnson and Boston Scientific continue to acquire mid-market specialists in defined therapeutic and technological areas.

Recent M&A Transactions: The Direction of Industry Consolidation

(1) Terumo × OrganOx Limited

United Kingdom, Announced in August 2025, Approximately USD 1.5 Billion

Terumo Corporation, listed on the TSE Prime Market under securities code 4543, recorded revenue of USD 6.91 billion for the fiscal year ended March 2025. In an announcement dated August 25, 2025, Terumo stated that it had entered into a definitive agreement to acquire all shares of Oxford-based OrganOx Limited for a total consideration of approximately USD 1.5 billion, as disclosed through Terumo’s investor information.

OrganOx is an innovator in normothermic machine-perfusion systems that allow donor organs to be preserved and assessed outside the body for extended periods. Through the acquisition, Terumo is entering the organ-transplantation field on a substantial scale and intends to expand transplant opportunities for patients worldwide.

The acquisition of a European medical device specialist for approximately USD 1.5 billion by a Japanese medical device manufacturer demonstrates that the sector has entered a phase in which Japanese global players are actively acquiring mid-market and growth businesses in the United States and Europe. For owners of Japanese mid-market companies, the transaction also demonstrates the seriousness with which leading Japanese strategic buyers are pursuing external growth.

(2) Olympus × BioProtect Ltd.

Israel, Completed in June 2026, Approximately USD 270 Million

Olympus Corporation, listed on the TSE Prime Market under securities code 7733 and holding a leading global position in endoscopy, announced on May 26, 2026 that it had entered into a definitive agreement to acquire all outstanding shares of Israeli medical device manufacturer BioProtect Ltd. The acquisition was completed on June 1, 2026, according to Olympus’ May 26, 2026 press release and its June 2, 2026 completion announcement.

• Acquisition consideration: USD 270 million
• A portion of the consideration was retained for a defined period, subject to the continued operation of the business
• Strategic objective: Expansion of Olympus’ urology portfolio and strengthening of solutions for prostate cancer treatment

Olympus has been concentrating management resources on medical devices. After divesting its scientific-solutions business to Bain Capital for approximately USD 2.85 billion, it continued to acquire businesses in its designated core areas.

The combined strategy of concentrating capital on core activities while separating non-core businesses is also relevant to mid-market owners. M&A can be used not only for full-company succession but also to reshape a portfolio by selling activities that fit another owner better and allocating resources toward the company’s strongest therapeutic or technological areas.

(3) Medius Holdings × Makoto Medical Instruments

March 2024: Staged Acquisition of a Regional Medical Device Distributor

Medius Holdings, listed on the TSE Prime Market under securities code 3154 and principally engaged in medical device distribution, entered into a basic agreement on October 24, 2023 to acquire shares in Makoto Medical Instruments, a long-established medical device dealer founded in 1947 and headquartered in Chuo, Yamanashi Prefecture.

The parties entered into a definitive agreement in February 2024, and on March 1, 2024 Medius acquired 39,000 of the company’s 60,000 outstanding shares, representing 65% of the total, according to Medius Holdings’ transaction progress disclosure. The parties were also considering the eventual acquisition of the remaining shares through a share exchange.

The transaction is a representative case in which a long-established regional dealer becomes a core part of a listed group’s strategy to strengthen support for regional healthcare providers and expand its sales network. The integration of a 76-year-old independent distributor into a listed platform at the point of generational succession provides a particularly relevant precedent for owners of independent medical device dealers in Kansai and other regional markets.

(4) Yamashita Health Care Holdings × Kagoshima Ortho Medical

December 2023: Acquisition of an Orthopedic Specialist Distributor

Yamashita Health Care Holdings, listed on the TSE Standard Market under securities code 9265, acquired all shares of Kagoshima Ortho Medical, an independent medical device distributor specializing in orthopedic products in Kagoshima, in December 2023.

The transaction brought a highly specialized regional distributor into a broader medical device distribution group. It demonstrates that a company does not need a nationwide footprint to attract strategic interest. A strong position in a defined specialty, such as orthopedics, dialysis, ophthalmology or dentistry, can itself provide a clear acquisition rationale.

(5) Sysmex: Combining Organic Growth and Strategic Alliances

Kobe-based Sysmex has generally combined internal research and development with strategic partnerships rather than relying primarily on large acquisitions.

Under its long-term management strategy, VA33, which runs through fiscal 2033, Sysmex identifies three principal growth areas: expansion in immunochemistry and support for Alzheimer’s disease diagnostics; international development of the hinotori surgical robot through Medicaroid, its joint venture with Kawasaki Heavy Industries; and the industrialization of regenerative and cell medicine, including an agreement with J-TEC concerning manufacturing automation. These initiatives are described in the Sysmex Report 2025.

A central feature of Sysmex’s business model is the recurring revenue generated by continuously selling reagents after placing diagnostic instruments at healthcare institutions. Reagents account for 61.7% of revenue.

The shift from generating earnings through equipment sales alone toward revenue from reagents, services and broader solutions provides an important reference point for mid-market medical device companies reviewing their own business models.

(6) Stryker × Inari Medical

United States, January 2025, Approximately USD 4.9 Billion

US medical device group Stryker announced in January 2025 that it would acquire Inari Medical, a specialist in devices for treating venous disease, for approximately USD 4.9 billion.

The transaction is a major example of a global medical technology company acquiring a mid-market growth business focused on a clearly defined therapeutic category.

For Japanese companies, this global trend creates three broad strategic alternatives: partnering with a leading international company in the company’s area of specialization, joining a domestic platform, or remaining independent while further developing a defensible niche.

Issues Owners Should Be Considering Now

When owners of mid-market and smaller medical device companies evaluate succession and M&A, the following issues are particularly important.

1. Organizing Pharmaceuticals and Medical Devices Act, QMS and Licensing Requirements

In medical device M&A, buyers place substantial emphasis on licenses, registrations and quality-management systems during due diligence.

Systematically organizing the company’s marketing authorization holder licenses, manufacturing registrations, QMS conformity assessments and history of interaction with the Pharmaceuticals and Medical Devices Agency can have a direct effect on valuation.

The relevant review should also establish which licenses and approvals are attached to the company, a particular site, a specific product or an individual responsible person, and what procedures will be required in connection with a change of control.

2. Providing Transparency on Customer Concentration and Trading History

Transaction history and continuity with hospitals, clinics, dispensing pharmacies and major healthcare distributors can support the predictability of cash flow.

Buyers will assess the duration and stability of these relationships, the degree of customer concentration, the role of tenders and annual agreements, and the company’s position within each region or clinical specialty. Quantifying regional market share and specialty-specific share is therefore important.

3. Recognizing the Value of Deep Specialization

The acquisitions of Makoto Medical Instruments by Medius Holdings and Kagoshima Ortho Medical by Yamashita Health Care Holdings demonstrate that a specialized regional independent distributor can attract an active buyer even without nationwide scale.

A focused position in orthopedics, dialysis, ophthalmology, dentistry or another clinical specialty can be more strategically valuable than a broader but less differentiated portfolio. Small scale is therefore not necessarily a disadvantage where the company provides access to a defined medical specialty, customer network or technical-sales capability.

4. Selecting the Appropriate Type of Buyer

Potential buyers include global medical device groups such as Olympus, Terumo, Sysmex, Stryker, Medtronic, Johnson & Johnson and Boston Scientific; Japanese mid-market manufacturers such as Nipro and Daiken Medical; medical device distribution groups such as Yamashita Health Care Holdings and Medius Holdings; and financial sponsors including Bain Capital, KKR and Patient Square Capital.

Each buyer category differs in investment policy, employee treatment, integration approach and exit strategy.

A global strategic buyer may prioritize technology, regulatory approvals and international commercialization. A domestic manufacturer may seek an adjacent product category or manufacturing capability. A distribution platform may value regional hospital coverage and specialist sales teams. A financial sponsor may focus on management depth, recurring revenue, add-on acquisitions and the potential for a later strategic sale or public offering.

5. Understanding That Specialty Position, Commercial Access and Regulatory Assets May Matter More Than a Single Product

The value of a medical device business does not necessarily rest primarily on the profitability of one product.

In many cases, the more important assets are the sales channel through which the product reaches healthcare providers, relationships with physicians and other medical professionals, regulatory approvals, reimbursement status, clinical evidence and the organization’s ability to support the product after installation or implantation.

The decisive valuation issue is therefore often the company’s strategic fit over the next three to five years rather than the current earnings of a single product line.

6. Maintaining a Cross-Border Perspective

Terumo’s acquisition of OrganOx and Olympus’ acquisition of BioProtect demonstrate that Japanese groups are actively acquiring overseas mid-market medical device companies. International medical device leaders also continue to acquire Japanese technology, distribution access and specialist capabilities.

Limiting the potential counterparty universe to Japan can therefore restrict both valuation and growth opportunities. A global buyer may have stronger commercialization capabilities, a more complementary product portfolio or a clearer strategic rationale than a domestic competitor.

Syntax Partners: Cross-Border M&A and Strategic Partnerships in Japan’s Medical Device Sector

Japan’s Medical Device Industry and M&A includes a substantial universe of privately held manufacturers, medical device distributors, specialist dealers, component companies, regulatory-asset holders and healthcare service businesses. Many have limited English-language disclosure and remain difficult to identify or assess through conventional financial databases.

Their strategic value may be embedded in proprietary technology, regulatory approvals, QMS infrastructure, physician and hospital relationships, specialist sales teams, regional distribution density, clinical knowledge, maintenance capabilities and access to defined therapeutic areas.

Syntax Partners supports international medical device manufacturers, healthcare groups, medical device distributors, technology companies and financial sponsors considering acquisitions, divestitures, capital alliances, joint ventures and other strategic partnerships in Japan.

(1) Strategic Market Assessment Grounded in a Detailed Understanding of Japan’s Medical Device Landscape

We analyze Japan’s medical device market by therapeutic area, product category, regulatory classification, distribution channel and regional coverage. Our assessment considers the Pharmaceuticals and Medical Devices Act, QMS requirements, reimbursement and specified medical-material pricing, import dependence, hospital procurement, specialist-dealer networks and the strategies of Japanese and international medical device groups.

We also assess relevant market positions across diagnostics, catheters, dialysis, infusion, anesthesia, pain management, orthopedics, ophthalmology, dentistry, surgical robotics, digital diagnostics and adjacent healthcare services.

Based on this analysis, we identify acquisition, divestiture and partnership themes aligned with the client’s product portfolio, regulatory strategy, commercial channels, geographic priorities and broader Asian growth objectives.

(2) Relationship-Led Access to Relevant Japanese Counterparties

We identify and approach Japanese medical device manufacturers, specialist distributors, regional dealers, component and OEM companies, maintenance providers, listed healthcare platforms, private equity funds and privately held healthcare businesses.

Many attractive Japanese companies are not formally for sale and may engage only through a credible, confidential and carefully positioned approach in Japanese. Our work therefore focuses on selected counterparties whose product portfolio, regulatory assets, therapeutic specialization, hospital relationships, sales capabilities and ownership objectives are aligned with the client’s strategy, rather than relying on broad-list outreach.

This approach is particularly important in Kansai and other regional markets, where strong companies may have deep positions in defined clinical specialties despite having limited English-language visibility.

(3) End-to-End Cross-Border Transaction Execution

We support international clients from initial market mapping and confidential counterparty outreach through NDA execution, valuation, transaction structuring, management discussions, due diligence, negotiation of definitive agreements, closing and initial post-merger integration planning.

Transactions in Japan’s medical device sector require particular attention to licenses and registrations, QMS systems, PMDA interaction history, product approvals, reimbursement, adverse-event and complaint records, distributor and manufacturer agreements, physician relationships, inventory and working-capital requirements, technical-sales personnel, maintenance obligations and change-of-control procedures.

We help clients evaluate these factors, translate the target’s technological, regulatory and commercial strengths into the transaction rationale, and manage the linguistic, cultural and relationship aspects of transaction execution in Japan.

(4) Regulatory, Commercial and Integration Planning

Medical device transactions often require regulatory and commercial workstreams to proceed in parallel.

Working with the client and relevant legal, regulatory, tax and technical advisers, we support the planning required to preserve regulatory continuity, maintain product supply, retain specialist personnel, communicate with manufacturers and distributors, and protect relationships with hospitals and medical professionals.

Where appropriate, the transaction structure may involve a full acquisition, majority or minority investment, capital and business alliance, joint venture, product or business carve-out, or a staged acquisition similar to the Medius Holdings and Makoto Medical Instruments case.

If your organization is considering an acquisition, divestiture, capital alliance, joint venture, distribution partnership or other strategic transaction involving a Japanese medical device manufacturer, distributor, specialist dealer, component company or related healthcare business, Syntax Partners would be pleased to discuss how we can assist. We welcome both early-stage market discussions and live transaction mandates relating to Japan’s Medical Device Industry and M&A.